Ganderton R H, Stanley K K, Field C E, Coghlan M P, Soos M A, Siddle K
Department of Clinical Biochemistry, University of Cambridge, Addenbrooke's Hospital, U.K.
Biochem J. 1992 Nov 15;288 ( Pt 1)(Pt 1):195-205. doi: 10.1042/bj2880195.
A mouse monoclonal antibody (CT-1) was prepared against the C-terminal peptide sequence of the human insulin receptor beta-subunit (KKNGRILTLPRSNPS). The antibody reacted with native human and rat insulin receptors in solution, whether or not insulin was bound and whether or not the receptor had undergone prior tyrosine autophosphorylation. The antibody also reacted specifically with the receptor beta-subunit on blots of SDS/polyacrylamide gels. Preincubation of soluble receptors with antibody increased the binding of 125I-insulin approx. 2-fold. The antibody did not affect insulin-stimulated autophosphorylation, but increased the basal autophosphorylation rate approx. 2-fold. The amino acid residues contributing to the epitope for CT-1 were defined by construction and screening of an epitope library. Oligonucleotides containing 23 random bases were synthesized and ligated into the vector pCL627, and the corresponding peptide sequences expressed as fusion proteins in Escherichia coli were screened by colony blotting. Reactive peptides were identified by sequencing the oligonucleotide inserts in plasmids purified from positive colonies. Six different positive sequences were found after 900,000 colonies had been screened, and the consensus epitope was identified as GRVLTLPRS. Phosphorylation of the threonine residue within this sequence (corresponding to the known phosphorylation site Thr-1348 in the insulin receptor) decreased the affinity of antibody binding approx. 100-fold, as measured by competition in an e.l.i.s.a. Antibody CT-1 was used for immunoaffinity isolation of insulin receptor from detergent-solubilized human placental or rat liver microsomal membranes. Highly purified receptor was obtained in 60% yield by binding to CT-1-Sepharose immunoadsorbent and specific elution with a solution of peptide corresponding to the known epitope. This approach to purification under very mild conditions may in principle be used with any protein for which an antibody is available and for which a peptide epitope or 'mimotope' can be identified.
制备了一种针对人胰岛素受体β亚基C末端肽序列(KKNGRILTLPRSNPS)的小鼠单克隆抗体(CT-1)。该抗体可与溶液中的天然人及大鼠胰岛素受体发生反应,无论胰岛素是否结合,也无论受体是否先前经历过酪氨酸自身磷酸化。该抗体还能与SDS/聚丙烯酰胺凝胶印迹上的受体β亚基特异性反应。抗体与可溶性受体预孵育可使125I胰岛素的结合增加约2倍。该抗体不影响胰岛素刺激的自身磷酸化,但使基础自身磷酸化速率增加约2倍。通过构建和筛选表位文库确定了构成CT-1表位的氨基酸残基。合成了含23个随机碱基的寡核苷酸并连接到载体pCL627中,通过菌落印迹法筛选在大肠杆菌中表达为融合蛋白的相应肽序列。通过对从阳性菌落纯化的质粒中的寡核苷酸插入片段进行测序来鉴定反应性肽。在筛选了900,000个菌落后发现了6种不同的阳性序列,一致表位被鉴定为GRVLTLPRS。通过酶联免疫吸附测定中的竞争实验测定,该序列中苏氨酸残基的磷酸化(对应于胰岛素受体中已知的磷酸化位点Thr-1348)使抗体结合亲和力降低约100倍。抗体CT-1用于从去污剂溶解的人胎盘或大鼠肝微粒体膜中免疫亲和分离胰岛素受体。通过与CT-1-琼脂糖免疫吸附剂结合并用对应于已知表位的肽溶液进行特异性洗脱,以60%的产率获得了高度纯化的受体。这种在非常温和条件下的纯化方法原则上可用于任何有可用抗体且能鉴定肽表位或“模拟表位”的蛋白质。